Geng W, Schwab A J, Horie T, Goresky C A, Pang K S
Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
J Pharmacol Exp Ther. 1998 Feb;284(2):480-92.
The hepatocellular uptake of the glutathione conjugate of bromosulfophthalein (BSPGSH) was examined in Eisai hyperbilirubinemic rats (EHBR; originating from Sprague-Dawley rats), which lacked the ATP-dependent canalicular transport for non-bile acid organic anions, a trend common to other mutant rat strains (TR- and GY, originating from Wistar rats). Single-pass perfused rat liver experiments were conducted with BSPGSH (26-257 microM) using the multiple indicator dilution technique. The steady-state extraction ratio of BSPGSH was close to zero due to lack of biliary excretion. After the introduction of a bolus dose containing vascular (51Cr-labeled red blood cells), interstitial (125I-labeled albumin and [14C]sucrose) and cellular space (D2O) indicators and [3H]BSPGSH into the portal vein, the outflow dilution profile of [3H]BSPGSH was found to display a protracted declining profile (tailing) at low input BSPGSH concentrations; the tail disappeared at higher BSPGSH concentrations. When data were fitted with the barrier-limited model of Goresky as used previously for BSPGSH for the Sprague-Dawley rat (SDR), model fitting was found to evoke an additional "deep pool" within the hepatocyte to account for the "tail" component. The deep pool became evident for the EHBR because biliary excretion of BSPGSH was absent and the rate of return from the deep pool was slow. The concentration of BSPGSH within the deep pool was estimated to be 12 +/- 8 times that in the cytosol. The binding of BSPGSH to EHBR S9 (effective binding concentration of 53 microM and a binding association constant KA of 2.4 x 10(4) M-1), however, was found to be lower than that of SDR S9 and could not account for the late-in-time data. The influx permeability-surface area product was concentration dependent and decreased from 0.27 to 0.01 ml.sec-1.g-1 with increasing BSPGSH concentration; the throughput component, or the portion of the dose that goes through the liver without entering the hepatocyte, increased with increasing concentration. The trends were characteristic of carrier-mediated transport and were similar to those found for the uptake of BSPGSH in SDR.
在卫材高胆红素血症大鼠(EHBR,源自斯普拉格 - 道利大鼠)中检测了溴磺酞谷胱甘肽共轭物(BSPGSH)的肝细胞摄取情况,该大鼠缺乏非胆汁酸有机阴离子的ATP依赖性胆小管转运,这是其他突变大鼠品系(TR和GY,源自Wistar大鼠)的常见趋势。使用多指示剂稀释技术,对BSPGSH(26 - 257 microM)进行了单通道灌注大鼠肝脏实验。由于缺乏胆汁排泄,BSPGSH的稳态提取率接近零。在将含有血管(51Cr标记的红细胞)、间质(125I标记的白蛋白和[14C]蔗糖)和细胞间隙(D2O)指示剂以及[3H]BSPGSH的推注剂量引入门静脉后,发现[3H]BSPGSH的流出稀释曲线在低输入BSPGSH浓度下呈现出延长的下降曲线(拖尾);在较高的BSPGSH浓度下拖尾消失。当数据用先前用于斯普拉格 - 道利大鼠(SDR)的BSPGSH的Goresky屏障限制模型拟合时,发现模型拟合会在肝细胞内引发一个额外的“深池”来解释“拖尾”成分。对于EHBR,深池变得明显,因为BSPGSH没有胆汁排泄且从深池返回的速率很慢。深池内BSPGSH的浓度估计是细胞质中的12±8倍。然而,发现BSPGSH与EHBR S9的结合(有效结合浓度为53 microM,结合缔合常数KA为2.4×10(4) M-1)低于SDR S9,并且无法解释后期数据。流入渗透表面积乘积与浓度有关,随着BSPGSH浓度的增加从0.27降至0.01 ml·sec-1·g-1;通量成分,即未进入肝细胞而通过肝脏的剂量部分,随着浓度增加而增加。这些趋势是载体介导转运的特征,并且与在SDR中发现的BSPGSH摄取趋势相似。